For samples related to COVID-19 click here to request a quote.

Viable Immuno-Oncology Cell Samples for Research

Our inventory includes fresh Leukopaks and cryovial Leukapheresis-derived cell fractions for immuno-oncology research. Our biorepository consists of CD3+, CD4+, CD8+, B Cells (CD19), and NK Cells (CD56). All viable immuno-oncology cell samples are collected in the United States under IRB-approved protocols. We can provide Leukopak and Leukapheresis samples from Pancreatic, Prostate, and Colorectal cancer patients within 2-4 weeks. Other cancer types may be provided as needed—just ask.


The CD3 T cell co-receptor is being used to help develop new anti-cancer drug treatments. Molecules are being designed to alter the co-stimulatory signal and help the T-cell recognize cancer cells and become fully activated.


Maximizing CD4+ T cells can help improve outcomes in cancer immunotherapy strategies by optimizing the magnitude and quality of the cytotoxic T lymphocytes (CTL) response. Cancer immunotherapy aims to promote the activity of cytotoxic T lymphocytes (CTLs) within a tumor.


Use CD8 + T cells in the tumor immunity cycle. The cells are primed and activated towards effector cytotoxic T lymphocytes (CTLs) to make durable and efficient anti-tumor immune responses. CD8 + T cells are used with cells of innate immunity—such as dendritic cells (DCs) and natural killer (NK) cells with CD4 + T cells—in adaptive immunity.

B Cells (CD19)

B cells can directly present tumor-associated antigens to T cells. They can also produce antibodies that increase antigen presentation to T cells or kill tumor cells. CD19 protein is used to diagnose cancers that arise from B cell types. Notable cell types include B cell lymphomas, acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL).

NK Cells (CD56)

Natural killer (NK) cells can kill multiple adjacent cells quickly if they show surface markers associated with oncogenic transformation. Research shows that NK cells are poised to become key components for multipronged therapeutic cancer strategies.

Request Quote

Request more information…

Request Information